Affymax, Inc. (NASDAQ:AFFY) a biopharmaceutical company that engages in discovering, developing, and delivering therapies that improve the lives of patients with kidney diseases, and other serious and life-threatening illnesses is currently down (-5.80 ...
Related articles »